Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $24.2 million.

  • 4D Molecular Therapeutics' Accumulated Expenses rose 1295.35% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 1295.35%. This contributed to the annual value of $18.9 million for FY2024, which is 5705.84% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Accumulated Expenses stood at $24.2 million, which was up 1295.35% from $19.2 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Accumulated Expenses high stood at $24.2 million for Q3 2025, and its period low was $4.9 million during Q2 2021.
  • Over the past 5 years, 4D Molecular Therapeutics' median Accumulated Expenses value was $8.9 million (recorded in 2022), while the average stood at $10.9 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Accumulated Expenses crashed by 749.01% in 2021 and then soared by 11007.46% in 2024.
  • 4D Molecular Therapeutics' Accumulated Expenses (Quarter) stood at $7.7 million in 2021, then grew by 14.54% to $8.9 million in 2022, then skyrocketed by 35.45% to $12.0 million in 2023, then surged by 57.06% to $18.9 million in 2024, then grew by 28.19% to $24.2 million in 2025.
  • Its Accumulated Expenses was $24.2 million in Q3 2025, compared to $19.2 million in Q2 2025 and $16.2 million in Q1 2025.